Bhanji Muna — SEC Form 4 filings
SEC reporting owner CIK 1846905. 20 Form 4 filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-05-16 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 8 filings — 15,846 shares, $465,677 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 4,589 shares @ $26.67 ($122,367) in VERACYTE, INC., filed 2025-06-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERACYTE, INC. (VCYT) | Director | 7 | — | 4 legs · 11,862 sh · $313,415 | 3 |
| CYTOKINETICS INC (CYTK) | Director | 5 | — | 2 legs · 3,454 sh · $147,367 | 6 |
| Intellia Therapeutics, Inc. (NTLA) | Director | 5 | — | 2 legs · 530 sh · $4,895 | 6 |
| ARDELYX, INC. (ARDX) | Director | 3 | — | — | 5 |
Form 4 filings — Bhanji Muna
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 1,864 @ $42.97 | EDGAR |
| 2026-06-18 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 26,455 @ $0 · Grant/award (A): 39,715 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-10 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | CYTOKINETICS INC (CYTK) | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 9,321 @ $0 | EDGAR |
| 2025-06-23 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 41,551 @ $0 · Grant/award (A): 54,059 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 4,589 @ $26.67 | EDGAR |
| 2025-06-13 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | CYTOKINETICS INC (CYTK) | Sale (S): 1,454 @ $29.73 | EDGAR |
| 2025-05-14 | 4 | CYTOKINETICS INC (CYTK) | Grant/award (A): 7,333 @ $0 · Grant/award (A): 10,880 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 265 @ $8.50 | EDGAR |
| 2025-01-31 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 265 @ $9.97 | EDGAR |
| 2024-06-17 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 11,473 @ $0 | EDGAR |
| 2024-06-17 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 40,243 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 7,737 @ $0 · Grant/award (A): 11,515 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 3,870 @ $20.32 | EDGAR |
| 2024-06-10 | 4 | CYTOKINETICS INC (CYTK) | Sale (S): 2,000 @ $52.07 | EDGAR |
| 2024-05-30 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 1,539 @ $21 | EDGAR |
| 2024-05-16 | 4 | CYTOKINETICS INC (CYTK) | Grant/award (A): 5,600 @ $0 · Grant/award (A): 3,636 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1846905 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →